AEON Biopharma
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 10
- Market Cap
- $36.1M
- Website
- http://www.aeonbiopharma.com
- Introduction
AEON Biopharma, Inc. is a biopharmaceutical company. It engages in the business of developing proprietary botulinum toxin complex, ABP-450 injection, for debilitating medical conditions. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Irvine, CA.
Clinical Trials
4
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- AEON Biopharma, Inc.
- Target Recruit Count
- 666
- Registration Number
- NCT05016661
- Locations
- 🇺🇸
MDFirst Research, Chandler, Arizona, United States
🇺🇸Elite Clinical Studies, LLC, Phoenix, Arizona, United States
🇺🇸Arizona Neuroscience Research, Phoenix, Arizona, United States
Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical Dystonia
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- AEON Biopharma, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT04871451
- Locations
- 🇺🇸
Arizona Neuroscience Research, Phoenix, Arizona, United States
🇺🇸Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States
🇺🇸Neuro Pain Medical Center, Fresno, California, United States
A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- AEON Biopharma, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT04849988
- Locations
- 🇺🇸
Arizona Neuroscience Research, Phoenix, Arizona, United States
🇺🇸Movement Disorder Center of Arizona, Scottsdale, Arizona, United States
🇺🇸Parkinson's and Movement Disorder Institute, Fountain Valley, California, United States
Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults
- Conditions
- Migraine
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- AEON Biopharma, Inc.
- Target Recruit Count
- 797
- Registration Number
- NCT04845178
News
AEON Biopharma Appoints Rob Bancroft as New CEO to Lead ABP-450 Therapeutic Development
AEON Biopharma has appointed industry veteran Rob Bancroft as Chief Executive Officer to lead the company's development of ABP-450 for therapeutic applications.
Cervical Dystonia Therapeutic Pipeline Shows Promise with Novel Therapies
The cervical dystonia therapeutics market is poised for growth, driven by advancements in R&D and the emergence of novel treatment options.
AEON Biopharma Achieves Positive Outcome in FDA Biosimilar Advisory Meeting for ABP-450
AEON Biopharma is aligned with the FDA on the 351(k) regulatory pathway for ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA).